A case report published in Frontiers in Neuroscience describes something that, by everything we thought we knew about Alzheimer's, should not have been possible. An 80-year-old woman. Ten years of Alzheimer's. Five years reduced to single syllables. Chronic incontinence. Dependent on caregivers for nearly everything. This is the stage of the disease we consider irreversible — the lights, we assume, are simply gone. Her family gave her a single high dose of psilocybin — 5 grams of mushrooms. She slept for about 19 hours. Then she woke up. And she began to talk. For hours. She told autobiographical stories. She recalled memories no one had heard from her in years. She recognized family members. She cracked jokes. Her mobility, her communication, her bladder control — functions lost for years — temporarily returned. Then, over the following days, it faded again. Let me be clear about what this is and isn't, because a story this extraordinary demands honesty. This is a single case report. One patient. Not a trial. It was not placebo-controlled. We cannot rule out coincidence or other factors. Nobody should try this — high-dose psilocybin in a frail 80-year-old is genuinely dangerous, and it is not a treatment. The authors themselves call for rigorous studies. But here is why it stops me cold, and why it matters far beyond one woman. We have long assumed advanced Alzheimer's represents permanent destruction — that the abilities are gone because the neurons that held them are gone. This case suggests something different and profound: that some of those capacities may not be destroyed, but disconnected. Locked behind broken network connectivity that psilocybin — which acts on serotonin receptors, drives neuroplasticity, and temporarily reorganizes how brain regions talk to each other — briefly reopened. The person was still in there. The door was just shut. I've written about this same pattern elsewhere in medicine — psychedelics unlocking function that disease had hidden rather than erased. The recurring theme of this era: what we called permanent may sometimes be dormant. This one case proves nothing. It does something arguably more important. It asks a question we didn't know we were allowed to ask: How much of an aging, failing brain is truly gone — and how much is simply waiting to be switched back on?

Eli Lilly is expanding heavily into neuroscience with a deal valued at $2.8 billion upfront to acquire AtaiBeckley. The deal could reach up to $3.8 billion if milestones are met.

The instinct when work piles up is to push harder. But neuroscience suggests a different approach: sometimes the fastest way forward is to intentionally slow down. The Italians have a phrase for it: il dolce far niente—"the sweetness of doing nothing."

Reality is not fragmented. It is one seamless, mercilessly interconnected system where every domain bleeds into every other without permission. History is psychology inscribed across time. Psychology is neuroscience wearing a human mask. Neuroscience dissolves into biology, which reveals evolution, which exposes culture, which births religion, which encodes mythology, which forges symbolism, which shapes language, which sculpts thought, which awakens consciousness, only for consciousness to loop back and question the entire chain. The same archetypes surface in Sumerian tablets and modern advertising campaigns. The same cycles of expansion, hubris, stagnation, and collapse repeat from Rome to the Soviet Union to the algorithmic empires rising today. Power concentrates through identical mechanisms whether in ancient courts, central banks, or social media platforms. Belief systems operate like operating systems, installing narratives that feel like truth until the next upgrade or crash exposes their code. Look at the patterns. Civilizations rise on shared myths and fall on accumulated lies. Economies boom on credit and illusion, then fracture under the weight of unpayable reality. Technologies accelerate human capability while exposing human frailty. All of this now forces the oldest question anew... What is intelligence, what is consciousness, and what remains sacred when code can mimic both? Biotechnology invites us to rewrite our own source code while we still barely understand the moral operating system that should govern it. Human beings are pattern seeking animals armed with savanna brains navigating planetary scale complexity. We crave certainty in a probabilistic universe. We trade long term truth for short term belonging. We normalize the monstrous one compromise at a time until the center cannot remain. Cognitive biases, status games, tribal signaling, fear of ostracism, these ancient circuits still drive boardrooms, elections, and revolutions. Trauma echoes through generations. Incentives shape behavior more reliably than ideals. Power corrupts because the architecture of dominance was wired long before language existed. Yet the same species that builds debt pyramids and weapons of mass distraction also composed symphonies, split the atom, decoded its own genome, and launched minds beyond the visible. We contain both the abyss and the stubborn light that refuses to look away. Consciousness may be the universe experiencing itself through fragile, temporary vessels, flawed, magnificent, and still capable of astonishing courage. We stand at a convergence unlike any before. Exponential technology collides with ancient human nature on a finite planet. Narrative warfare fractures societies faster than truth can travel. Systems grow too complex for any single mind to grasp, yet too fragile to survive their own unintended consequences. The old maps are burning. The new territory demands synthesis, not specialization. Radical honesty, not comforting ideology. First principles thinking over inherited dogma. Most will look away. The pattern has always favored sleepwalking. Comfort feels safer than clarity. Division feels easier than integration. But a few feel the ache of the deeper pattern. They sense the wheel turning faster, the stakes rising from national to civilizational to existential. They recognize that small surrenders today compound into collapse tomorrow. The choice remains brutally simple. Awaken to the interconnected architecture or become another echo in the repeating cycle. See the relationships between power and belief, technology and meaning, incentive and outcome, or repeat the tragedies with better tools. Integrate the hard truths from every domain or let the fragmented illusions steer us over the edge. This moment is not just another chapter. It is a threshold. The species that survived ice ages and world wars now faces the question of whether it can survive its own success. The universe does not owe us continuation. It only offers the raw material and the brief, burning opportunity to become something wiser than we were. Most never will. Some already have. The rest of the story is still unwritten, and the pen sits in our hands whether we admit it or not.

Since introducing Empirical Research Assistance last fall, Google Research scientists have been using it to address real-world applications in epidemiology, cosmology, atmospheric monitoring, and neuroscience, providing a hint of AI’s transformational capabilities to accelerate scientific discoveries. Learn more →

Researchers have reported an interesting new approach that may help the brain clear Alzheimer’s-related waste more effectively. In a mouse model of Alzheimer’s disease, a copper-based compound called Cu(ATSM) was tested and showed promising results. Over a 56-day period, treated mice had about a 42% reduction in amyloid-beta, a protein strongly associated with Alzheimer’s, along with an improvement of nearly 44% in spatial learning performance. Rather than focusing only on breaking down amyloid-beta after it builds up, this study looked at why the brain struggles to remove it in the first place. Normally, the brain relies on a waste clearing system linked to the blood–brain barrier. One important part of this system is a group of transport proteins called P-glycoprotein (P-gp), which help move harmful substances, including amyloid-beta, out of the brain and into the bloodstream. In Alzheimer’s, these transport pumps often become less active. The study found that Cu(ATSM) increased the abundance of P-gp pumps by about 24% in the Alzheimer’s mouse model. This appeared to enhance the brain’s natural clearance system, allowing more amyloid-beta to be removed rather than accumulating into plaques. The findings suggest Alzheimer’s may involve not only the formation of toxic proteins, but also a failure in the brain’s waste-removal machinery. That shifts the focus toward potential treatments that restore clearance systems, rather than only targeting existing deposits. However, the work is still early-stage. These results come from laboratory and animal research, and the compound has not yet been shown to improve symptoms or slow disease progression in humans. Cu(ATSM) has already been investigated in other neurological conditions, such as Parkinson’s disease and ALS, which may help guide future research into Alzheimer’s therapies. Study referenced: “Cu(ATSM) Restores Blood-Brain Barrier Abundance of P-Glycoprotein and Improves Cognitive Function in the APP/PS1 Mouse Model of Alzheimer’s Disease,” ACS Chemical Neuroscience.